Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from China Shineway Pharmaceutical Group Limited ( (HK:2877) ).
China Shineway Pharmaceutical Group reported that first-quarter 2026 turnover fell 18.0% year on year to RMB624 million, based on unaudited management accounts. The shift in product mix saw injection and TCM formula granule revenues decline sharply, while soft capsule and granule products posted solid growth.
Turnover from injection products slumped 35.9% to RMB168 million and TCM formula granules dropped 32.8% to RMB164 million, highlighting pressure on some of the group’s legacy lines. By contrast, soft capsule sales rose 32.1% to RMB107 million and granule products increased 24.8% to RMB146 million, suggesting demand is pivoting toward these formats and potentially reshaping Shineway’s revenue structure, prompting a cautionary note to shareholders and investors.
More about China Shineway Pharmaceutical Group Limited
China Shineway Pharmaceutical Group Limited is a Hong Kong-listed pharmaceutical company focused on traditional Chinese medicine (TCM) and related pharmaceutical products. Its core portfolio spans injection formulations, soft capsules, granules and TCM formula granules, serving the mainland Chinese healthcare market through hospital and retail channels.
Average Trading Volume: 1,125,963
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$7.17B
Find detailed analytics on 2877 stock on TipRanks’ Stock Analysis page.